{"page_content": "5 Amgen 2010 Environmental Sustainability ReportSince 1980, Amgen has been a pioneer, leader, and innovator in \nmedical biotechnology  . Headquartered in Thousand Oaks, California, \nwith facilities and partners in 50 countries, Amgen discovers, develops, \nand markets medicines that have helped millions of people around the \nworld fight cancer, bone disease, kidney disease, rheumatoid arthritis, \nand other serious illnesses  . We aspire to reflect our mission to serve \npatients and improve human health in all the ways we conduct our \nbusiness  . Managing our operations in an environmentally sustainable \nmanner is consistent with this vision  . We have found that integrating \nenvironmental sustainability concepts into our business supports our \ncorporate values and contributes positive benefits in the development \nof our products and in our company\u2019s operations  . \n2010 company profile metrics\nNet sales $14 .660 billion\n\u201cAdjusted\u201d net income* $5 .024 billion \n\u201cAdjusted\u201d R&D expenses* $2 .773 billion\nNumber of staff 17,400\nCountries in which Amgen \noperates 50\nPolitical contributions (U  .S .)\u2020 $1 .144 million \n*\u201cAdjusted\u201d net income and \u201cadjusted\u201d R&D expenses are non-GAAP financial measures  . \nSee page 27 for reconciliations to U  .S . Generally Accepted Accounting Principles (GAAP)  . \nAdditional information regarding economic performance by Amgen is available in our \n2010 Annual Report and Financial Summary  .\n\u2020Additional information regarding political contributions by Amgen is available in the Summary \nof data section in this report and in the  Corporate Governance section at www  .amgen  .com .Recognition\nAmgen received several industry awards in 2010  . In September, \nAmgen was awarded the 11th Annual International Prix Galien Prize \nfor Best Biopharmaceutical Research and Development for Nplate\u00ae \n(romiplostim)  . Also, Amgen earned the Scrip  Award for Best New Drug, \nProlia\u00ae (denosumab)  . In addition, Amgen was included on Fortune \u2019s \nlist of the most admired companies and contenders in America  . \nIn the area of environmental sustainability, local municipalities have \nrecognized Amgen with numerous awards over the years in areas \nsuch as waste reduction, resource conservation, and wastewater \ndischarge compliance . Details regarding these awards can be found \nin the Environmental Sustainability section at www  .amgen  .com .\nProducts\nAranesp\u00ae (darbepoetin alfa)\nEnbrel\u00ae (etanercept)\nEPOGEN\u00ae (Epoetin alfa)\nNeulasta\u00ae (pegfilgrastim)\nNEUPOGEN\u00ae (Filgrastim)\nNplate\u00ae (romiplostim)\nProlia\u00ae (denosumab)\nSensipar\u00ae (cinacalcet)\nVectibix\u00ae (panitumumab)\nXGEVA\u2122 (denosumab)\nFor additional information about Amgen\u2019s products, including \nimportant safety information, visit www  .amgen  .com for links \nto the product websites  .A pioneer in developing \n   biotechnology medicines\n", "metadata": {"source": "NASDAQ_AMGN_2010.pdf", "page": 4, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}